Digital Cognitive Behavior Therapy Program for Suicide Prevention (TM2)
Status
Conditions
Treatments
Details and patient eligibility
About
This study evaluates the efficacy of Thrive, a computerized cognitive behavior therapy program, to reduce depression and anxiety symptoms and to reduce suicidal thinking among adults. The first 450 participants will participate in a randomized waitlist controlled trial. The remaining 550 participants will be provided the program immediately upon enrolling
Full description
The efficacy of Thrive has been studied among patient and community populations and has shown to effectively reduce depression and anxiety symptoms among adults with moderate to severe depression symptoms at baseline.
This study will examine whether Thrive can also reduce suicidal thinking for persons exhibiting at least moderate depression symptoms. The first phase of the study will implement a randomized waitlist controlled trial. The second phase of the study will examine the effects in a open trial. Outcome assessments will occur at baseline, 4- and 8-weeks (12- and 16-weeks for the waitlist group) with a 6-month follow-up assessment for all participants.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Montana resident
- 18+ years old
- Have regular access to broadband internet
- PHQ-9 score greater than 4
Exclusion criteria
- No Montana residency
- < 18 years old
- No broadband internet access
- PHQ-9 score less than 5
Trial design
Primary purpose
Allocation
Interventional model
Masking
725 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal